Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2020-04-27 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
2019年年度审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" which translates to "Audit Report". It contains detailed audit opinions, audit basis, key audit matters, and extensive financial statement notes. The content includes auditor's responsibilities, management responsibilities, and detailed accounting policies, which are typical components of a standalone audit report. The document is about the audit of the financial statements for the year ended December 31, 2019, for Zhejiang Tailin Biotechnology Co., Ltd. It is not an annual report (10-K) because it does not include the full company activity report or management discussion and analysis, but focuses on the audit opinion and related audit information. The length of the document (15,000 characters) and the detailed audit content confirm it is a full audit report, not just an announcement or certification. Therefore, the correct classification is Audit Report / Information (AR). FY 2019
2020-04-27 Chinese
董事、监事和高级管理人员持有和买卖本公司股票管理制度（2020年4月）
Governance Information Classification · 95% confidence The document is a detailed internal policy regarding the management of stock holdings and trading by the company's directors, supervisors, and senior management. It outlines rules, procedures, and responsibilities related to insider trading, reporting, lock-up periods, and penalties for violations. The content focuses on governance and compliance related to insider share dealings rather than reporting financial results, announcements, or regulatory filings. It does not contain financial statements, earnings data, or voting results. It is not a report of director share transactions but a management policy document. Therefore, the document best fits the category of Governance Information (CGR), which covers internal rules and governance practices.
2020-04-27 Chinese
2019年度监事工作报告
Management Reports Classification · 90% confidence The document is titled as the "2019年度监事工作报告" which translates to "2019 Supervisory Board Work Report". It details the supervisory board's activities, oversight of financial conditions, compliance with laws, internal control evaluations, and plans for the next year. It is a report from the supervisory board rather than a full annual report or audit report. The document length is 2418 characters, which is relatively short and focused on supervisory work rather than comprehensive financial statements or audit opinions. It does not contain full financial statements or detailed audit results, so it is not an Annual Report (10-K) or Audit Report (AR). It is not a regulatory filing or announcement but a formal report on supervisory activities. Therefore, the best fitting category is Management Reports (MDA), which covers management's detailed explanation of financial results, business trends, and outlook, including supervisory board reports on governance and oversight.
2020-04-27 Chinese
关于2020年第一季度报告披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (354 characters) stating that the company's 2020 first quarter report has been disclosed on an official website. It does not contain the actual financial data or report itself, but rather directs investors to where the report can be found. This fits the pattern of a Report Publication Announcement (RPA) rather than the report itself (IR).
2020-04-27 Chinese
第二届监事会第六次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the second session of the Supervisory Board's sixth meeting of Zhejiang Tailin Biotechnology Co., Ltd. It includes approvals of various reports such as the 2019 Annual Report, 2020 Q1 Report, 2019 Supervisory Board Work Report, profit distribution proposals, financial statements, internal control self-assessment, remuneration plans, and other financial and governance matters. The document repeatedly states that the full reports are published separately on the official disclosure website (cninfo.com.cn) and that these resolutions will be submitted to the 2019 Annual General Meeting for approval. The document itself does not contain the full financial reports or detailed financial data but is a formal announcement of the Supervisory Board's review and approval of these reports and proposals. This fits the profile of a Regulatory Filing (RNS) as it is a regulatory announcement of meeting resolutions and approvals rather than the reports themselves. The document length (4542 characters) and content support this classification rather than it being the actual Annual Report (10-K) or Interim Report (IR).
2020-04-27 Chinese
关于全资子公司变更经营范围并完成工商变更登记的公告
Regulatory Filings Classification · 100% confidence The document is an announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding the change in business scope of its wholly-owned subsidiary and the completion of the related industrial and commercial registration. It details the previous and new business scope, registration information, and confirms the completion of the registration process. There is no financial data, no mention of financial results, no regulatory certifications, no voting results, no management changes, no legal proceedings, no capital changes, and no report attachments. The document is a formal announcement about a business scope change and registration update, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2020-04-16 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.